Relypsa Inc. (RLYP) 19.34 $RLYP
Relypsa Announces New Employment Inducement Grants
GlobeNewswire - Mon Jun 06, 3:15PM CDT
Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on June 1, 2016, the compensation committee of the company's board of directors granted 2 new employees options to purchase an aggregate of 6,250 shares of the company's common stock with a per share exercise price of $19.86, the closing trading price on the grant date, and 3,125 restricted stock units. The stock options and restricted stock units were granted pursuant to the Relypsa, Inc. 2014 Employment Commencement Incentive Plan, which was approved by the company's board of directors in June 2014 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company.
RLYP: 19.34 (+0.48)
Relypsa (RLYP) Shows Strength: Stock Moves 8.8% Higher
Zacks Equity Research - Zacks Investment Research - Mon May 30, 7:15AM CDT
Relypsa, Inc. (RLYP) shares rose almost 9% in the last trading session.
RLYP: 19.34 (+0.48), AZN: 27.97 (-0.99)
Relypsa Up on CRL for AstraZeneca Hyperkalemia Drug
Zacks Equity Research - Zacks Investment Research - Mon May 30, 6:30AM CDT
Shares of Relypsa, Inc. (RLYP) gained after AstraZeneca (AZN) received a CRL regarding its NDA for its hyperkalemia candidate, ZS-9.
RLYP: 19.34 (+0.48), PFE: 35.29 (-0.02), AZN: 27.97 (-0.99), BMY: 72.65 (-0.08)
Relypsa Submits Supplemental New Drug Application to FDA Requesting Label Changes for Veltassa Based on Phase 1 Drug-Drug Interaction Studies
GlobeNewswire - Wed May 25, 3:15PM CDT
Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that the company has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) requesting label changes for Veltassa(patiromer) for oral suspension based on results of 12 Phase 1 drug-drug interaction studies in healthy volunteers.
RLYP: 19.34 (+0.48)
Data from New Analyses of Studies with Veltassa(R) Presented at 53rd European Renal Association Congress
GlobeNewswire - Sun May 22, 10:00AM CDT
Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that data from new analyses of studies with Veltassa(patiromer) for oral suspension were presented at the 53 Congress of the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) in Vienna.
RLYP: 19.34 (+0.48)
Why Under Armour, Relypsa, and HollyFrontier Slumped Today
Dan Caplinger, The Motley Fool - Motley Fool - Wed May 04, 5:33PM CDT
Image: Under Armour. Wednesday put continued pressure on the stock market, and investors appeared to focus on ongoing pressure in the energy sector and fears about global macroeconomic conditions in pushing major market benchmarks lower on the day....
UA: 38.38 (-0.28), RLYP: 19.34 (+0.48), HFC: 27.03 (+0.19)
Relypsa reports 1Q loss
Automated Insights - Wed May 04, 5:02PM CDT
REDWOOD CITY, Calif. (AP) _ Relypsa Inc. (RLYP) on Wednesday reported a loss of $54.8 million in its first quarter.
RLYP: 19.34 (+0.48)
Relypsa Reports First Quarter 2016 Financial Results
GlobeNewswire - Wed May 04, 3:07PM CDT
Relypsa Management to Host Conference Call/Webcast this Afternoon at 5:00 p.m. ET/2:00 p.m. PT
RLYP: 19.34 (+0.48)
Why Relypsa Inc.'s Shares Are Crashing 16% Today
Todd Campbell, The Motley Fool - Motley Fool - Wed May 04, 11:01AM CDT
SOURCE: RELYPSA, INC. What: After closing an offering of $150 million in senior-secured loans yesterday, shares of Relypsa are trading lower by 15.9% at 11:00 a.m. EST Wednesday morning. So what: The company has borrowed $150 million in...
RLYP: 19.34 (+0.48)
Relypsa Announces $150 Million Debt Financing
GlobeNewswire - Tue May 03, 3:15PM CDT
Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced the closing of $150 million in aggregate principal amount of senior secured term loans (the "Loans"
, led by funds advised by Athyrium Capital Management and joined by HealthCare Royalty Partners. The Loans are senior secured obligations of Relypsa and will mature on April 27, 2022, unless earlier prepaid or repaid in accordance with their terms prior to such date. The Loans bear interest at a rate of 11.5 percent per year, to be paid quarterly beginning June 15, 2016 and include an interestâ?only period of 30 months, which may be extended up to 48 months upon meeting certain conditions.
RLYP: 19.34 (+0.48)
Relypsa to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
GlobeNewswire - Mon May 02, 3:15PM CDT
Relypsa, Inc. (Nasdaq:RLYP) today announced that John A. Orwin, president and chief executive officer, will present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 10, 2016 at 3:00 p.m. PT.
RLYP: 19.34 (+0.48)
Data from New Analyses of Studies with Veltassa(R) Presented at National Kidney Foundation 2016 Spring Clinical Meetings
GlobeNewswire - Thu Apr 28, 5:00PM CDT
Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced data from new analyses of studies with Veltassa(patiromer) for oral suspension were presented at the National Kidney Foundation (NKF) 2016 Spring Clinical Meetings in Boston.
RLYP: 19.34 (+0.48)
Relypsa to Report First Quarter 2016 Financial Results and Host Conference Call on Wednesday, May 4, 2016
GlobeNewswire - Wed Apr 27, 3:16PM CDT
Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that the company will report first quarter 2016 financial results on Wednesday, May 4, 2016, after the close of financial markets. Management will host a conference call and live audio webcast on the same afternoon at 5:00 p.m. ET (2:00 p.m. PT).
RLYP: 19.34 (+0.48)
NKF Recognizes Relypsa with Inaugural Corporate Innovator Award for First Drug Approved by FDA for Hyperkalemia in 50 Years
PR Newswire - Tue Apr 26, 8:53AM CDT
The National Kidney Foundation (NKF) is honoring Relypsa, Inc. with its first-ever Corporate Innovator Award in recognition of the biopharmaceutical company's breakthrough development of Veltassa, the first new hyperkalemia (high-potassium) treatment medicine approved by the FDA in over 50 years. This new drug will offer an additional treatment option for patients with kidney failure who have high potassium levels.
RLYP: 19.34 (+0.48)
Vifor Fresenius Medical Care Renal Pharma and Relypsa Announce Submission of Marketing Authorization Application Requesting European Approval of Veltassa(R) for the Treatment of Hyperkalemia
GlobeNewswire - Mon Apr 25, 7:36AM CDT
Vifor Fresenius Medical Care Renal Pharma Ltd. (VFMCRP), a common company of Galenica and Fresenius Medical Care, and Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that VFMCRP has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for Veltassa (patiromer) for oral suspension. VFMCRP is seeking approval of Veltassa for the treatment of hyperkalemia, or elevated blood potassium levels, in the European Union (EU) through the EU centralized procedure.
RLYP: 19.34 (+0.48)
Relypsa Announces Upcoming Veltassa(R) Data Presentations at National Kidney Foundation 2016 Spring Clinical Meetings
GlobeNewswire - Thu Apr 21, 3:16PM CDT
Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that new analyses from studies of Veltassa(patiromer) for oral suspension will be presented at the National Kidney Foundation (NKF) 2016 Spring Clinical Meetings, taking place April 27-May 1 in Boston.
RLYP: 19.34 (+0.48)
Relypsa's Wild Rumors and the Facts that Were Ignored
OptionVol - Sun Apr 17, 3:01PM CDT
Relypsa, Inc. Our purpose is to provide institutional research to all investors and break the information monopoly held by the top .1%. PREFACE Relypsa (RLYP) is a small-cap clinical stage biopharmaceutical company that a wild week based on th...
AZN: 27.97 (-0.99), MRK: 56.81 (-0.37), RLYP: 19.34 (+0.48), IBB: 267.60 (-5.98), SNY: 39.41 (-1.45)
Relypsa Announces New Employment Inducement Grants
GlobeNewswire - Mon Jun 06, 3:15PM CDT
Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on June 1, 2016, the compensation committee of the company's board of directors granted 2 new employees options to purchase an aggregate of 6,250 shares of the company's common stock with a per share exercise price of $19.86, the closing trading price on the grant date, and 3,125 restricted stock units. The stock options and restricted stock units were granted pursuant to the Relypsa, Inc. 2014 Employment Commencement Incentive Plan, which was approved by the company's board of directors in June 2014 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company.
RLYP: 19.34 (+0.48)
Relypsa (RLYP) Shows Strength: Stock Moves 8.8% Higher
Zacks Equity Research - Zacks Investment Research - Mon May 30, 7:15AM CDT
Relypsa, Inc. (RLYP) shares rose almost 9% in the last trading session.
RLYP: 19.34 (+0.48), AZN: 27.97 (-0.99)
Relypsa Up on CRL for AstraZeneca Hyperkalemia Drug
Zacks Equity Research - Zacks Investment Research - Mon May 30, 6:30AM CDT
Shares of Relypsa, Inc. (RLYP) gained after AstraZeneca (AZN) received a CRL regarding its NDA for its hyperkalemia candidate, ZS-9.
RLYP: 19.34 (+0.48), PFE: 35.29 (-0.02), AZN: 27.97 (-0.99), BMY: 72.65 (-0.08)
Relypsa Submits Supplemental New Drug Application to FDA Requesting Label Changes for Veltassa Based on Phase 1 Drug-Drug Interaction Studies
GlobeNewswire - Wed May 25, 3:15PM CDT
Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that the company has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) requesting label changes for Veltassa(patiromer) for oral suspension based on results of 12 Phase 1 drug-drug interaction studies in healthy volunteers.
RLYP: 19.34 (+0.48)
Data from New Analyses of Studies with Veltassa(R) Presented at 53rd European Renal Association Congress
GlobeNewswire - Sun May 22, 10:00AM CDT
Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that data from new analyses of studies with Veltassa(patiromer) for oral suspension were presented at the 53 Congress of the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) in Vienna.
RLYP: 19.34 (+0.48)
Why Under Armour, Relypsa, and HollyFrontier Slumped Today
Dan Caplinger, The Motley Fool - Motley Fool - Wed May 04, 5:33PM CDT
Image: Under Armour. Wednesday put continued pressure on the stock market, and investors appeared to focus on ongoing pressure in the energy sector and fears about global macroeconomic conditions in pushing major market benchmarks lower on the day....
UA: 38.38 (-0.28), RLYP: 19.34 (+0.48), HFC: 27.03 (+0.19)
Relypsa reports 1Q loss
Automated Insights - Wed May 04, 5:02PM CDT
REDWOOD CITY, Calif. (AP) _ Relypsa Inc. (RLYP) on Wednesday reported a loss of $54.8 million in its first quarter.
RLYP: 19.34 (+0.48)
Relypsa Reports First Quarter 2016 Financial Results
GlobeNewswire - Wed May 04, 3:07PM CDT
Relypsa Management to Host Conference Call/Webcast this Afternoon at 5:00 p.m. ET/2:00 p.m. PT
RLYP: 19.34 (+0.48)
Why Relypsa Inc.'s Shares Are Crashing 16% Today
Todd Campbell, The Motley Fool - Motley Fool - Wed May 04, 11:01AM CDT
SOURCE: RELYPSA, INC. What: After closing an offering of $150 million in senior-secured loans yesterday, shares of Relypsa are trading lower by 15.9% at 11:00 a.m. EST Wednesday morning. So what: The company has borrowed $150 million in...
RLYP: 19.34 (+0.48)
Relypsa Announces $150 Million Debt Financing
GlobeNewswire - Tue May 03, 3:15PM CDT
Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced the closing of $150 million in aggregate principal amount of senior secured term loans (the "Loans"
, led by funds advised by Athyrium Capital Management and joined by HealthCare Royalty Partners. The Loans are senior secured obligations of Relypsa and will mature on April 27, 2022, unless earlier prepaid or repaid in accordance with their terms prior to such date. The Loans bear interest at a rate of 11.5 percent per year, to be paid quarterly beginning June 15, 2016 and include an interestâ?only period of 30 months, which may be extended up to 48 months upon meeting certain conditions. RLYP: 19.34 (+0.48)
Relypsa to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
GlobeNewswire - Mon May 02, 3:15PM CDT
Relypsa, Inc. (Nasdaq:RLYP) today announced that John A. Orwin, president and chief executive officer, will present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 10, 2016 at 3:00 p.m. PT.
RLYP: 19.34 (+0.48)
Data from New Analyses of Studies with Veltassa(R) Presented at National Kidney Foundation 2016 Spring Clinical Meetings
GlobeNewswire - Thu Apr 28, 5:00PM CDT
Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced data from new analyses of studies with Veltassa(patiromer) for oral suspension were presented at the National Kidney Foundation (NKF) 2016 Spring Clinical Meetings in Boston.
RLYP: 19.34 (+0.48)
Relypsa to Report First Quarter 2016 Financial Results and Host Conference Call on Wednesday, May 4, 2016
GlobeNewswire - Wed Apr 27, 3:16PM CDT
Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that the company will report first quarter 2016 financial results on Wednesday, May 4, 2016, after the close of financial markets. Management will host a conference call and live audio webcast on the same afternoon at 5:00 p.m. ET (2:00 p.m. PT).
RLYP: 19.34 (+0.48)
NKF Recognizes Relypsa with Inaugural Corporate Innovator Award for First Drug Approved by FDA for Hyperkalemia in 50 Years
PR Newswire - Tue Apr 26, 8:53AM CDT
The National Kidney Foundation (NKF) is honoring Relypsa, Inc. with its first-ever Corporate Innovator Award in recognition of the biopharmaceutical company's breakthrough development of Veltassa, the first new hyperkalemia (high-potassium) treatment medicine approved by the FDA in over 50 years. This new drug will offer an additional treatment option for patients with kidney failure who have high potassium levels.
RLYP: 19.34 (+0.48)
Vifor Fresenius Medical Care Renal Pharma and Relypsa Announce Submission of Marketing Authorization Application Requesting European Approval of Veltassa(R) for the Treatment of Hyperkalemia
GlobeNewswire - Mon Apr 25, 7:36AM CDT
Vifor Fresenius Medical Care Renal Pharma Ltd. (VFMCRP), a common company of Galenica and Fresenius Medical Care, and Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that VFMCRP has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for Veltassa (patiromer) for oral suspension. VFMCRP is seeking approval of Veltassa for the treatment of hyperkalemia, or elevated blood potassium levels, in the European Union (EU) through the EU centralized procedure.
RLYP: 19.34 (+0.48)
Relypsa Announces Upcoming Veltassa(R) Data Presentations at National Kidney Foundation 2016 Spring Clinical Meetings
GlobeNewswire - Thu Apr 21, 3:16PM CDT
Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that new analyses from studies of Veltassa(patiromer) for oral suspension will be presented at the National Kidney Foundation (NKF) 2016 Spring Clinical Meetings, taking place April 27-May 1 in Boston.
RLYP: 19.34 (+0.48)
Relypsa's Wild Rumors and the Facts that Were Ignored
OptionVol - Sun Apr 17, 3:01PM CDT
Relypsa, Inc. Our purpose is to provide institutional research to all investors and break the information monopoly held by the top .1%. PREFACE Relypsa (RLYP) is a small-cap clinical stage biopharmaceutical company that a wild week based on th...
AZN: 27.97 (-0.99), MRK: 56.81 (-0.37), RLYP: 19.34 (+0.48), IBB: 267.60 (-5.98), SNY: 39.41 (-1.45)
